Brokerages Set BioScrip, Inc. (BIOS) PT at $3.94
Shares of BioScrip, Inc. (NASDAQ:BIOS) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $3.94.
Several research firms have weighed in on BIOS. ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub downgraded BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and lifted their target price for the company from $3.25 to $3.75 in a research report on Thursday, August 10th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a research report on Thursday, August 10th.
BioScrip (NASDAQ:BIOS) last released its earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The business had revenue of $218.11 million during the quarter, compared to the consensus estimate of $220.05 million. BioScrip’s quarterly revenue was down 6.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.14) earnings per share.
In other news, Director Coliseum Capital Management, L sold 2,846,941 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $2.93, for a total transaction of $8,341,537.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael G. Bronfein sold 27,000 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $2.69, for a total value of $72,630.00. Following the transaction, the director now directly owns 129,669 shares of the company’s stock, valued at $348,809.61. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,760,419 shares of company stock valued at $11,144,519. Corporate insiders own 0.80% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Gilder Gagnon Howe & Co. LLC grew its position in shares of BioScrip by 248.4% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock worth $41,298,000 after buying an additional 10,845,410 shares in the last quarter. FMR LLC grew its position in shares of BioScrip by 10.8% during the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after buying an additional 520,231 shares in the last quarter. Vanguard Group Inc. grew its position in shares of BioScrip by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock worth $12,204,000 after buying an additional 146,980 shares in the last quarter. Wynnefield Capital Inc. grew its position in shares of BioScrip by 2.7% during the first quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock worth $6,460,000 after buying an additional 100,000 shares in the last quarter. Finally, Alta Fundamental Advisers LLC grew its position in shares of BioScrip by 36.9% during the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after buying an additional 818,000 shares in the last quarter. 84.05% of the stock is owned by institutional investors and hedge funds.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.